RxDoctor Payments DataLook up a doctor →

Yuebing Li, MD

Neurology · Cleveland, OHNPI 1669482790

Payments from drug & device makers

$1,414,563in general payments, 2019–2025

Across 280 payments — averaging $5052.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$566K
  • Janssen Research & Development, LLC$397K
  • AstraZeneca$117K
  • Takeda Pharmaceuticals U.S.A., Inc.$111K
  • UCB SA$105K
  • Catalyst Pharmaceuticals, Inc.$99K
  • plus $20K from 10 others
$1,037in research payments, 2019–2025

Across 5 payments — averaging $207.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1K

What the payments were for

  • Consulting fees$33,61876%
  • Speaking & faculty fees$6,10014%
  • Travel & lodging$2,4666%
  • Food & beverage$2,0425%
  • Education$90%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,414,563 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$41,404
Medicare patients
261
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5015$241,755
Gamunex-CImmune Globul G/Gly/Iga Avg 4646$154,750
NuedextaDextromethorphan Hbr/Quinidine12$26,850
Mycophenolate Mofetil130$11,465
Pyridostigmine Bromide174$9,997
Azathioprine65$9,986
Gabapentin117$1,919
Prednisone226$1,332
Pregabalin34$846
Lidocaine11$541
Duloxetine Hcl32$332
Nortriptyline Hcl12$162
Tizanidine Hcl16$132
Trazodone Hcl12$60
Metoprolol Succinate12$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$122$241,75515 claims
Grifols USA, LLCGamunex-C$95$154,75046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 702 neurology providers in Ohio.

Other neurology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →